Authorised Therapeutic use (Phase IV) We are investigating the efficacy and safety of enhanced thromboprophylaxis during neoadjuvant treatments for pancreatic cancer.

Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease.

EU CTIS ID: 2024-512475-12-01

What this study is testing

Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.

  • Therapeutic use (Phase IV)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • An adult pancreatic cancer patient for whom neoadjuvant treatments are being planned due to pancreatic cancer.

You likely can't join if

  • The study excludes patients, if they have contraindications for using tinzaparin, are already on anticoagulant medication, have had any other active cancer in the past five years or have severe kidney failure or bleeding tendencies.

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

ObesityType 2 diabetesType 1 diabetesPrediabetesWeight lossMetabolic syndromeHigh cholesterolHigh triglyceridesHigh blood pressurePCOSHypothyroidismThyroid diseaseGoutFatty liver disease (NAFLD/NASH)Heart failureCoronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.